FR2565823A1 - PHARMACEUTICAL AND COSMETOLOGICAL PREPARATIONS CONTAINING VITAMIN A DERIVATIVES - Google Patents

PHARMACEUTICAL AND COSMETOLOGICAL PREPARATIONS CONTAINING VITAMIN A DERIVATIVES Download PDF

Info

Publication number
FR2565823A1
FR2565823A1 FR8504777A FR8504777A FR2565823A1 FR 2565823 A1 FR2565823 A1 FR 2565823A1 FR 8504777 A FR8504777 A FR 8504777A FR 8504777 A FR8504777 A FR 8504777A FR 2565823 A1 FR2565823 A1 FR 2565823A1
Authority
FR
France
Prior art keywords
oxo
acid
pharmaceutical
vitamin
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR8504777A
Other languages
French (fr)
Inventor
Werner Bollag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2565823A1 publication Critical patent/FR2565823A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92Oral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DES COMPOSITIONS PHARMACEUTIQUES OU COSMETIQUES CONTENANT EN TANT QUE SUBSTANCES ACTIVES L'ACIDE DE LA 4-OXO- OU DE LA 4-HYDROXY-13-CIS-VITAMINE A, PEUVENT ETRE UTILISEES POUR LE TRAITEMENT DE L'ACNE OU DE LA SEBORRHEE.PHARMACEUTICAL OR COSMETIC COMPOSITIONS CONTAINING, AS ACTIVE SUBSTANCES, THE ACID OF 4-OXO- OR 4-HYDROXY-13-CIS-VITAMIN A, MAY BE USED FOR THE TREATMENT OF ACNE OR SEBORRHEA.

Description

-1--1-

L'invention concerne des compositions pharma-  The invention relates to pharmaceutical compositions.

ceutiques ou cosmétiques qui se caractérisent en ce qu'elles contiennent de l'acide de la 4-oxo- ou de la 4-hydroxy-13-cis-vitamine A. Les acides de la 4-oxo- et de la 4-hydroxy-13- cis- vitamine A (en nomenclature systématique: acide  Ceuticals or cosmetics which are characterized in that they contain 4-oxo- or 4-hydroxy-13-cis-vitamin A acid. 4-oxo- and 4-hydroxy acids -13- cis- vitamin A (in systematic classification: acid

(Z,E,E,E)-3,7-diméthyl-9-(2,6,6-triméthyl-3-oxo-l-cyclo-  (Z, E, E, E) -3,7-dimethyl-9- (2,6,6-trimethyl-3-oxo-1-cyclo-

hexène-l-yl)-2,4,6,8-nonatétraénoique et acide (Z,E,E,E)  hexene-1-yl) -2,4,6,8-nonatetraenoic and acid (Z, E, E, E)

-3,7-diméthyl-9-(2,6,6-triméthyl-3-hydroxy-1l-cyclohexène-  -3,7-dimethyl-9- (2,6,6-trimethyl-3-hydroxy-11-cyclohexene-

1-yl)-2,4,6,8-nonatétraénoique respectivement) sont des  1-yl) -2,4,6,8-nonatetraenoic respectively) are

métabolites de l'acide de la 13-cis-vitamine A [J. Biol.  13-cis-vitamin A acid metabolites [J. Biol.

Chem. 255, 8057 (1980)].Chem. 255, 8057 (1980)].

On a maintenant trouvé que les acides de la 4-  We have now found that the acids of 4-

oxo- et de la 4-hydroxy-13-cis-vitamine A avaient une activité thérapeutique. En particulier, ces composés peuvent être utilisés pour le traitement de l'acné et  oxo- and 4-hydroxy-13-cis-vitamin A had therapeutic activity. In particular, these compounds can be used for the treatment of acne and

de la séborrhée.seborrhea.

Les compositions selon l'invention peuvent con-  The compositions according to the invention can

sister en compositions pour l'administration systémique ou pour l'application topique. On préfère les compositions  sister in compositions for systemic administration or for topical application. We prefer the compositions

pour l'administration orale, par exemple les capsules.  for oral administration, for example capsules.

Les compositions peuvent contenir avec les substances actives des produits auxiliaires pharmaceutiques usuels  The compositions may contain, with the active substances, usual pharmaceutical auxiliary products

tels que des liants, des matières de charge ou des anti-  such as binders, fillers or anti

oxydants. Une unité de dosage, par exemple une capsule,  oxidants. A dosing unit, for example a capsule,

peut contenir d'environ 10 à 100 mg de substance active.  may contain from about 10 to 100 mg of active substance.

Pour le traitement de l'acné et de la séborrhée, on peut administrer les substances actives aux humains  For the treatment of acne and seborrhea, the active substances can be administered to humans

à des posologies quotidiennes de 0,5 à 5 mg/kg, de pré-  at daily dosages of 0.5 to 5 mg / kg, pre-

férence de 1 à 2 mg/kg par voie orale.  ference of 1 to 2 mg / kg orally.

-2--2-

Pour l'application topique, les composés peu-  For topical application, the compounds may

vent être mis à l'état de solutions ou de lotions ou être introduits dans des produits de lavage des cheveux (shampooings). Les solutions, lotions et shampooings peuvent contenir environ 0,01 à 2%, de préférence 0,1 à 0, 5% de substance active et être appliqués sur la peau une ou plusieurs fois par jour ou utilisés (shampooings) une fois par jour ou une à deux fois par semaine pour  can be put in the form of solutions or lotions or be introduced into hair washing products (shampoos). Solutions, lotions and shampoos can contain about 0.01 to 2%, preferably 0.1 to 0.5% of active substance and can be applied to the skin one or more times a day or used (shampoos) once a day or once or twice a week for

le lavage des cheveux.washing the hair.

Les exemples qui suivent illustrent plus com-  The following examples illustrate more

plètement l'invention.completely the invention.

Exemple 1Example 1

Préparation des substances actives A 56,2 g de bromure de [5-(3-oxo-2,6,6triméthyl  Preparation of the active substances A 56.2 g of [5- (3-oxo-2,6,6 trimethyl) bromide

-1-cyclohexène-l-yl)-3-méthyl-2,4-pentadiényl]-triphényl-  -1-cyclohexene-1-yl) -3-methyl-2,4-pentadienyl] -triphenyl-

phosphonium et 11,4 g de 4-hydroxy-3-méthyl-2-buténolide dans 250 ml d'isopropanol, on ajoute à 0-5 C 94,3 ml de KOH 2,12N dans l'isopropanol (0,2 mole). On laisse le mélange de réaction au repos pendant 1 heure à 510 C puis on ramène à température ambiante. 30 mn plus tard, on coule le mélange de réaction dans une saumure à 5%, on acidifie par l'acide sulfurique et on extrait par l'acétate d'éthyle. On lave l'extrait organique à la saumure, on sèche et on évapore; on obtient un produit brut à partir duquel la cristallisation dans le mélange  phosphonium and 11.4 g of 4-hydroxy-3-methyl-2-butenolide in 250 ml of isopropanol, 94.3 ml of 2.12N KOH in isopropanol (0.2 mol) are added at 0-5 C. ). The reaction mixture is left to stand for 1 hour at 510 ° C. and then brought back to room temperature. 30 minutes later, the reaction mixture is poured into 5% brine, acidified with sulfuric acid and extracted with ethyl acetate. The organic extract is washed with brine, dried and evaporated; a crude product is obtained from which the crystallization in the mixture

hexane/acétate d'éthyle donne l'acide (E,E,Z,Z)-3,7-di-  hexane / ethyl acetate gives the acid (E, E, Z, Z) -3,7-di-

méthyl-9-(2,6,6-triméthyl-3-oxo-l-cyclohexène-l-yl)-2,4,  methyl-9- (2,6,6-trimethyl-3-oxo-1-cyclohexene-1-yl) -2.4,

6,8-nonatétraénoique pur fondant à 159-160 C.  6,8-pure nonatetraenoic melting at 159-160 C.

On traite 13,4 g de cet acide dans 600 ml de méthanol à 0 C par un excès de diazométhane. On laisse -3- le mélange de réaction revenir à température ambiante et au bout de 30 mn, on concentre; on obtient le (E, E, Z,Z)-3,7-diméthyl-9-(2,6,6-triméthyl-3-oxo-l-cyclohexène -l-yl)-2,4,6, 8-nonatétraénoate de méthyle à l'état de produit brut. On isomérise 14,2 g du produit brut dans  13.4 g of this acid are treated in 600 ml of methanol at 0 ° C. with an excess of diazomethane. The reaction mixture is allowed to return to ambient temperature and after 30 min, it is concentrated; (E, E, Z, Z) -3,7-dimethyl-9- (2,6,6-trimethyl-3-oxo-1-cyclohexene -l-yl) -2,4,6,8 are obtained -methyl nonatetraenoate in the form of a crude product. 14.2 g of the crude product are isomerized into

l'acétonitrile par 1,48 g de dichloro-bis-benzonitrile-  acetonitrile with 1.48 g of dichloro-bis-benzonitrile-

Pd (II) et 2,5 ml de triéthylamine. La purification par chromatographie donne le (Z,E,E,E)-3,7-diméthyl-9-(2,6,  Pd (II) and 2.5 ml of triethylamine. Purification by chromatography gives (Z, E, E, E) -3,7-dimethyl-9- (2,6,

6-triméthyl-3-oxo-l-cyclohexène-l-yl)-2,4,6,8-nonatétraé-  6-trimethyl-3-oxo-1-cyclohexene-1-yl) -2,4,6,8-nonatetraa-

noate de méthyle. On hydrolyse 13,3 g de cet ester par  methyl noate. 13.3 g of this ester are hydrolyzed by

chauffage de 30 mn avec une lessive de potasse hydro-  heating for 30 minutes with a hydro- potassium wash

éthanolique (13,8 g de KOH, 300 ml d'éthanol). On refroi-  ethanolic (13.8 g of KOH, 300 ml of ethanol). We cool

dit le mélange de réaction, on coule dans l'eau glacée,  says the reaction mixture, we run in ice water,

on acidifie par l'acide acétique et on extrait par l'acé-  acidified with acetic acid and extracted with acetic

tate d'éthyle. On lave l'extrait à la saumure, on sèche et on évapore; on fait cristalliser le produit brut dans le mélange hexane/acétate d'éthyle. La recristallisation dans le mélange acétate d'éthyle/hexane donne l'acide  ethyl tate. The extract is washed with brine, dried and evaporated; the crude product is crystallized from a hexane / ethyl acetate mixture. Recrystallization from ethyl acetate / hexane gives the acid

(Z,E,E,E)-3,7-diméthyl-9-(2,6,6-triméthyl-3-oxo-1l-cyclo-  (Z, E, E, E) -3,7-dimethyl-9- (2,6,6-trimethyl-3-oxo-1l-cyclo-

hexène-l-yl)-2,4,6,8-nonatétraénoique pur fondant à 164-  hexene-l-yl) -2,4,6,8-pure nonatetraenoic melting at 164-

166 C.166 C.

On traite 0,314 g d'acide (Z,E,E,E)-3,7-diméthyl  0.314 g of acid (Z, E, E, E) -3,7-dimethyl are treated

-9-(2,6,6-triméthyl-3-oxo-l-cyclohexène-l-yl)-2,4,6,8-  -9- (2,6,6-trimethyl-3-oxo-1-cyclohexene-1-yl) -2,4,6,8-

nonatétraénoique pendant 5 mn par du borohydrure de so-  nonatetraenoic for 5 min with sodium borohydride

dium dans le mélange méthanol/eau. On acidifie le mélange de réaction par l'acide acétique et on extrait par le chlorure de méthylène. On lave l'extrait par la saumure, on sèche, on évapore et on fait cristalliser dans le mélange acétate d'éthyle/hexane. On obtient l'acide (Z,  dium in the methanol / water mixture. The reaction mixture is acidified with acetic acid and extracted with methylene chloride. The extract is washed with brine, dried, evaporated and crystallized from the ethyl acetate / hexane mixture. We get the acid (Z,

E,E,E)-3,7-diméthyl-9-(2,6,6-triméthyl-3-oxo-l-cyclohe-  E, E, E) -3,7-dimethyl-9- (2,6,6-trimethyl-3-oxo-1-cyclohe-

xène-l-yl)-2,4,6,8-nonatétraénoique pur.  xene-1-yl) -2,4,6,8-pure nonatetraenoic.

-4--4-

Exemple 2Example 2

Préparation d'une capsule pour l'administration orale On broie une suspension aqueuse de 27% en poids de gélatine (Bloom 30), 41% en poids de maltodextrine MD 05, 7% en poids d'ascorbate de sodium et 25% en poids  Preparation of a capsule for oral administration An aqueous suspension of 27% by weight of gelatin (Bloom 30), 41% by weight of maltodextrin MD 05, 7% by weight of sodium ascorbate and 25% by weight are ground

d'acide (Z,E,E,E)-3,7-diméthyl-9-(2,6,6-triméthyl-3-oxo-  acid (Z, E, E, E) -3,7-dimethyl-9- (2,6,6-trimethyl-3-oxo-

l-cyclohexène-l-yl)-2,4,6,8-nonatétraénoique à une di-  l-cyclohexene-l-yl) -2,4,6,8-nonatetraenoic at one di-

mension de particule moyenne de 0,5 micron et on atomise.  average particle size of 0.5 micron and atomized.

On mélange dans chaque cas 25 mg de la poudre ainsi ob-  25 mg of the powder thus obtained are mixed in each case.

tenue, 20 mg d'Avicel PH 102, (cellulose microcristalline),  held, 20 mg of Avicel PH 102, (microcrystalline cellulose),

34 mg de lactose et 6 mg de Polyplasdone (polyvinylpyrro-  34 mg lactose and 6 mg Polyplasdone (polyvinylpyrro-

lidone réticulée; Crosspovidon) et on introduit dans des  crosslinked lidone; Crosspovidon) and we introduce in

capsules de gélatine.gelatin capsules.

Exemple 3Example 3

Préparation d'une lotionPreparation of a lotion

acide (Z,E,E,E)-3,7-diméthyl-9-acid (Z, E, E, E) -3,7-dimethyl-9-

(2,6,6-triméthyl-3-oxo-l-cyclohexène-  (2,6,6-trimethyl-3-oxo-1-cyclohexene-

l-yl)-2,4,6,8-nonatétraénoique 0,01 à 2,0 g - alcool éthylique 10,0 à 52, 0 g propylène-glycol à 50,0 g polyéthylène-glycol 0 à 50,0 g diméthylsulfoxyde 0 à50,0 g On dissout la substance active dans le mélange  l-yl) -2,4,6,8-nonatetraenoic 0.01 to 2.0 g - ethyl alcohol 10.0 to 52.0 g propylene glycol to 50.0 g polyethylene glycol 0 to 50.0 g dimethyl sulfoxide 0 to 50.0 g The active substance is dissolved in the mixture

des solvants.solvents.

Claims (4)

REVENDICATIONS 1. Composition pharmaceutique ou cosmétique carac-  1. Pharmaceutical or cosmetic composition charac- térisée en ce qu'elle contient l'acide de la 4-oxo- ou de la 4-hydroxy-13cis-vitamine A.  terized in that it contains the acid of 4-oxo- or 4-hydroxy-13cis-vitamin A. 2. Composition selon la revendication 1, sous la forme de capsules contenant 10 à 100 mg de substance active.2. Composition according to claim 1, in the form of capsules containing 10 to 100 mg of active substance. 3. Les acides de la 4-oxo- et de la 4-hydroxy-13-  3. The acids of 4-oxo- and 4-hydroxy-13- cis-vitamine A pour l'utilisation en tant que substances  cis-vitamin A for use as substances actives thérapeutiques ou cosmétiques.  therapeutic or cosmetic active ingredients. 4. Les acides de la 4-oxo- et de la 4-hydroxy-13-  4. The acids of 4-oxo- and 4-hydroxy-13- cis-vitamine A pour l'utilisation en tant que substances  cis-vitamin A for use as substances actives contre l'acné et la séborrhée.  active against acne and seborrhea.
FR8504777A 1984-04-02 1985-03-29 PHARMACEUTICAL AND COSMETOLOGICAL PREPARATIONS CONTAINING VITAMIN A DERIVATIVES Pending FR2565823A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1645/84A CH658387A5 (en) 1984-04-02 1984-04-02 PHARMACEUTICAL PREPARATIONS.

Publications (1)

Publication Number Publication Date
FR2565823A1 true FR2565823A1 (en) 1985-12-20

Family

ID=4215302

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8504777A Pending FR2565823A1 (en) 1984-04-02 1985-03-29 PHARMACEUTICAL AND COSMETOLOGICAL PREPARATIONS CONTAINING VITAMIN A DERIVATIVES

Country Status (13)

Country Link
JP (1) JPS60218372A (en)
AU (1) AU575386B2 (en)
BE (1) BE902055A (en)
CA (1) CA1243608A (en)
CH (1) CH658387A5 (en)
DE (1) DE3509455A1 (en)
DK (1) DK99085A (en)
FR (1) FR2565823A1 (en)
GB (1) GB2156676B (en)
IT (1) IT1184729B (en)
NL (1) NL8500855A (en)
SE (1) SE8501518L (en)
ZA (1) ZA852279B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282326C (en) * 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US5955109A (en) * 1985-12-18 1999-09-21 Advanced Polymer Systems, Inc. Methods and compositions for topical delivery of retinoic acid
US5879716A (en) * 1985-12-18 1999-03-09 Advanced Polymer Systems, Inc. Methods and compositions for topical delivery of benzoyl peroxide
IL90069A (en) * 1988-04-26 1994-04-12 Us Health 13-cis- retinoic acid for use in the preparation of a medicament for treating conglobate and nodulocystic acne
EP0802181B1 (en) * 1996-04-15 1999-12-22 F. Hoffmann-La Roche Ag Retinoids
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
EP1971331A2 (en) * 2005-12-09 2008-09-24 Basilea Pharmaceutica AG 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169103A (en) * 1978-04-12 1979-09-25 Hoffmann-La Roche Inc. Nonatetraenoic acid derivatives
WO1982002833A1 (en) * 1981-02-17 1982-09-02 Gail Sansone Bazzano The use of retinoids and their derivatives to increase the rate of growth of human scalp hair and to increase the rate of growth of fur in certain fur-bearing animals

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLINICAL RESEARCH, vol. 30, no. 1, 1982, page 160A; G. SANSONE-BAZZANO et al.: "Probable mode of action of retinoids in the suppression of achne, psoriasis and other skin deseases" *
CLINICAL RESEARCH, vol. 30, no. 2, 1982, page 607A; G. SANSONE-BAZZANO: "Probable mode of action of retinoids in the suppression of acne, psoriasis and other skin deseases" *
DRUG METAB. DISPOS., vol. 10, no. 3, 1982, pages 212-219, The American Society for Pharmacology and Experimental Therapeutics; F.M. VANE et al.: "Metabolism of 13-cis-retinoic acid by a rat liver 9000g supernatant preparation" *
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 24, no. 5, 1983, pages 689-694, Springer-Verlag; W.A. COLBURN et al.: "Pharmacokinetics of Isotretinoin and its major blood metabolite following a single oral dose to man" *
JOURNAL OF CHROMATROGRAPHY, vol. 227, no. 2, 1982, pages 471-484, Elsevier Scientific Publishin Co., Amsterdam, NL; F.M. VANE et al.: "Determination of 13-cis-retinoic acid and its major metabolite, 4-oxo-13-cis-retinoic acid, in human blood by reversed-phase high-performance liquid chromatography" *
THE MERCK INDEX, 10ième édition, 1983, page 1178, Merck & Co., Inc., Rahway, N.J., US *

Also Published As

Publication number Publication date
AU575386B2 (en) 1988-07-28
SE8501518D0 (en) 1985-03-27
IT8519907A0 (en) 1985-03-14
CH658387A5 (en) 1986-11-14
GB2156676A (en) 1985-10-16
IT1184729B (en) 1987-10-28
CA1243608A (en) 1988-10-25
GB8508443D0 (en) 1985-05-09
AU4083685A (en) 1985-10-10
DK99085A (en) 1985-10-03
ZA852279B (en) 1985-11-27
DK99085D0 (en) 1985-03-04
SE8501518L (en) 1985-10-03
BE902055A (en) 1985-09-30
DE3509455A1 (en) 1985-10-10
NL8500855A (en) 1985-11-01
GB2156676B (en) 1987-10-21
JPS60218372A (en) 1985-11-01

Similar Documents

Publication Publication Date Title
CA1247123A (en) Polysubstituted derivatives of naphtalene, and their preparation
CA1256378A (en) Pharmaceutical composition containing at least one naphtalenic derivative as active principle
LU86022A1 (en) POLYCYLIC AROMATIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS
CA1272448A (en) Pharmaceutical composition containing at least one benzonorbornen derivative as active principle
WO1986006064A1 (en) Naphthalenic derivatives with retinoid activity, preparation process thereof and medicinal and cosmetic compositions containing them
CH672638A5 (en)
CA1315674C (en) Pharmaceutical compositions containing at least one bicyclic aromatic derivative as an active ingredient
CA1294971C (en) Benzofurannic derivatives, process for preparing such and medicated compoundsand cosmetics containing said derivatives
EP0292348B1 (en) Polycyclic heterocyclic derivatives, proces for their preparation and their use in human and veterinary medicines
CA2209391C (en) New heterocyclic biaryl compounds and their use in human or veterinary medicine and in cosmetics
FR2565823A1 (en) PHARMACEUTICAL AND COSMETOLOGICAL PREPARATIONS CONTAINING VITAMIN A DERIVATIVES
CA1328465C (en) Eicosanoid sulfides and their application as pharmaceutical and cosmetic compounds
EP0297995B1 (en) Polycyclic aromatic compounds, process for their preparation and their use in human and animal medicine and in cosmetics
EP0409728A2 (en) Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics
EP0179697B1 (en) Retinoic-acid derivatives, process for their preparation and medicinal and cosmetic compositions containing them
EP0360637B1 (en) Benzofuran compounds, process for their preparation, pharmaceutical and cosmetic compositions containing them and use of these compositions
CH656132A5 (en) N-CARBAMOYL DERIVATIVES OF ISOTHIAZOLO- (5,4B) PYRIDINE ONE-3 THEIR PREPARATION PROCESS, AND COSMETIC COMPOSITIONS CONTAINING THEM.
LU86388A1 (en) NOVEL CHROMANE AND THIOCHROMANE DERIVATIVES, PREPARATION METHOD THEREOF, AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM
CA1255599A (en) Pharmaceutical compositions containing a 1-substituted methoxy-4-trimethyl-1,2,3,6 benzene derivative
FR2580631A1 (en) HYDROXY-1 ACYLOXY-8 ACYL-10 ANTHRONES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS
FR2567402A1 (en) NOVEL PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING DIHYDROXY-1,8 PHENYL-10 ANTHRONE-9 AS ACTIVE INGREDIENT, AND PROCESS FOR PREPARING THE ACTIVE INGREDIENT
CA1247122A (en) Unsaturated camphor derivatives, and their preparation
FR2573755A1 (en) Polysubstituted naphthalene derivatives, process for preparing them and their application in the pharmaceutical and cosmetic fields
EP0409729A1 (en) Bi-aromatic thioesters, process for their preparation and their use in human or veterinary medicine and in cosmetics
FR2573071A1 (en) 2-[N-(2-Hydroxy-1,1-dimethylethyl)amino]-1-phenylethanol which is useful, in particular, as an anti-inflammatory, and process for preparing it